2025.01,Canagliflozin,Markets and News,API,Canagliflozin Hemihydrate,928672-86-0
Title: Comprehensive Overview of Canagliflozin (Invokana): Market Trends, Patent Status, and Competitive Landscape.png)
Abstract:
Canagliflozin, marketed under the brand name Invokana, is an SGLT2 (sodium-glucose cotransporter-2) inhibitor used in the treatment of type 2 diabetes and chronic kidney disease. This paper provides an overview of Canagliflozin, including its development, approval history, patent status, market performance, competition, and recent developments. It also explores the drug’s sales figures globally and in China, its generic drug competition, and the key API involved. Additionally, recent news related to the product is examined, with a focus on its clinical advancements and market impact.
Keywords:
Canagliflozin, Invokana, SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, global sales, China market, generic drugs, API, patent status.
1. Introduction:
Canagliflozin is a type 2 diabetes treatment that works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys, thereby preventing glucose reabsorption into the blood and promoting glucose excretion in the urine. Initially developed by Johnson & Johnson, Canagliflozin is marketed under the brand name Invokana and has become a key player in the SGLT2 inhibitor class. Its primary indications include type 2 diabetes and chronic kidney disease, with recent studies showing its effectiveness in reducing cardiovascular events and improving patient outcomes in these populations.
This paper delves into Canagliflozin’s market journey, patent details, sales figures globally and in China, its competition, and the emergence of generic alternatives.
2. Manufacturer and Research Development:
Canagliflozin was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J). The compound was designed as part of J&J's strategy to address unmet needs in the management of type 2 diabetes, particularly focusing on a new mechanism of action targeting the kidneys. Canagliflozin was first discovered in 2004 and underwent extensive clinical trials before receiving approval.
The drug’s unique mechanism of action, which involves inhibiting SGLT2, allows it to help control blood glucose levels, reduce hypertension, and provide renal protection in patients with diabetes and chronic kidney disease. Canagliflozin was initially marketed in 2013 and has since been approved for multiple indications, including for reducing the risk of cardiovascular events in high-risk patients with diabetes.
3. Marketing Approval and Timeline:
FDA Approval (2013): The U.S. FDA approved Canagliflozin for the treatment of type 2 diabetes in March 2013. This approval marked a significant milestone in diabetes treatment, as it was the first SGLT2 inhibitor to be approved in the U.S.
European Medicines Agency (EMA) Approval (2014): Canagliflozin was approved by the European Medicines Agency in 2014 for type 2 diabetes management, under the brand name Invokana.
Chronic Kidney Disease Indication (2019): In 2019, the FDA expanded the indication for Canagliflozin to include the treatment of chronic kidney disease (CKD), particularly in patients with type 2 diabetes, following positive results from large-scale clinical trials.
Approval in China (2017): Canagliflozin was approved for marketing in China in 2017, allowing its use for managing type 2 diabetes. This was followed by additional indications for cardiovascular risk reduction and chronic kidney disease.
4. Patent Status of Core Compounds:
The patent for the core compound, Canagliflozin, was filed by Janssen Pharmaceuticals and is set to expire in 2025 in major markets such as the United States. However, J&J has additional patents surrounding the compound, including those for its crystalline form and formulations, which may extend market exclusivity.
Once the patent expires, generic versions of Canagliflozin are expected to enter the market. This will likely trigger competition from other pharmaceutical companies looking to offer more affordable alternatives. However, Janssen has also filed for secondary patents related to combination therapies, which may delay the entry of generics in some markets.
5. Marketing Time in China:
Canagliflozin entered the Chinese market in 2017 and was approved by the China National Medical Products Administration (NMPA). Since its approval, the drug has been marketed as a treatment for type 2 diabetes, and it has been embraced by both physicians and patients due to its efficacy in controlling blood sugar levels and its renal benefits.
The approval of Canagliflozin in China is a significant milestone, as diabetes prevalence is growing rapidly in the country. This has positioned Invokana as a key player in the market for SGLT2 inhibitors alongside other competitors like Dapagliflozin.
6. Global Sales and Market Performance:
Canagliflozin has been commercially successful since its approval. In 2022, global sales for Canagliflozin (Invokana) were estimated at $2.5 billion USD. The drug’s strong performance can be attributed to its dual benefits for managing blood glucose and its positive impact on cardiovascular and kidney health. The market for SGLT2 inhibitors has grown significantly due to increasing awareness of their cardiovascular benefits, making them a preferred choice in diabetes and heart disease management.
7. Sales in China:
In China, Canagliflozin has seen increasing sales since its market approval. By 2023, the annual sales in China were estimated at approximately ¥1 billion. The growing diabetic population and the increasing adoption of newer therapies, including SGLT2 inhibitors, have contributed to Canagliflozin’s market penetration. The availability of Canagliflozin has been a crucial factor in expanding access to effective diabetes medications in both urban and rural areas.
8. Market Competition:
Canagliflozin faces significant competition from other SGLT2 inhibitors, which have similar indications and mechanisms of action. The main competitors include:
These drugs also offer cardiovascular and renal protection, and they are increasingly being prescribed as first-line treatments for type 2 diabetes and kidney disease, which makes the competition more intense. The market for SGLT2 inhibitors is expected to grow substantially in the coming years, as the drugs become increasingly recognized for their pleiotropic benefits beyond glucose control.
9. Generic Drugs and Market Entry:
As the patent for Canagliflozin expires in 2025, several pharmaceutical companies are preparing to launch generic versions. Companies like Teva Pharmaceuticals, Mylan, and Sandoz are expected to introduce generic Canagliflozin once the patent protection ends.
In addition to the generic versions of Canagliflozin, combination therapies with other diabetes medications, such as metformin, may also be developed to capture a broader segment of the market.
10. Key API and Related Technologies:
Active Pharmaceutical Ingredient
928672-86-0
Canagliflozin Hemihydrate, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
http://m.bilibili221.cc/product_en.html
11. News Developments in the Last Six Months:
August 2024: New data from a large-scale clinical trial demonstrated that Canagliflozin significantly reduces the progression of kidney disease in patients with type 2 diabetes. This reinforced its value as a dual-purpose medication for both diabetes and kidney protection.
November 2024: Johnson & Johnson announced the launch of a new combination therapy involving Canagliflozin and metformin, aiming to offer patients more comprehensive diabetes management with improved convenience.
December 2024: China’s NMPA approved new guidelines for the use of Canagliflozin in patients with heart failure, expanding its indication in the growing Chinese cardiovascular market.
12. Conclusion:
Canagliflozin (Invokana) has proven itself as a valuable treatment for type 2 diabetes, chronic kidney disease, and cardiovascular conditions, benefiting from its unique mechanism as an SGLT2 inhibitor. With a strong presence in both global and Chinese markets, it is a key player in the growing sector of diabetes and cardiovascular treatments. The upcoming patent expiration in 2025 will bring generic competition, but Canagliflozin’s clinical benefits may continue to sustain its market share. The ongoing developments and expansions into new therapeutic areas ensure that Canagliflozin will remain an important drug for years to come.
References:
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
